IFNA2 and cutaneous melanoma: To assess the feasibility and toxicity profile of high-dose interferon alpha-2b (IFN-α-2b) in the adjuvant treatment of patients with cutaneous malignant melanoma outside the reference ECOG 1684 clinical trial, we conducted a prospective follow-up in an identical population of patients (cutaneous melanoma, T4 and/or N1) treated by intravenous IFN-α-2b:20 MIU m−2, 5 days a week for 4 weeks; and subcutaneous:10 MIU m−2, 3 times a week for 11 months.